Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.410
-0.075-1.37%
Volume:72.67M
Turnover:392.83M
Market Cap:101.08B
PE:35.54
High:5.550
Open:5.550
Low:5.355
Close:5.485
52wk High:7.886
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:1.75
T/O Rate:0.39%
Dividend:0.12
Dividend Rate:2.22%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.65
PE(LYR):35.54
PS:2.56

Loading ...

Sino Biopharmaceutical Stock Falls 1.4% in Hong Kong

Dow Jones
·
Yesterday

Hong Kong Regulators Issue Joint Statement on Audit Opinions; Nasdaq Slides 1.25%

Stock News
·
Yesterday

Sino Biopharma Unit Completes Patient Enrollment for Pulmonary Disease Drug Trial

MT Newswires Live
·
Oct 08

SanegeneBio Said to Weigh Hong Kong IPO Next Year After Confidential Filing

Stock News
·
Oct 08

Sino Biopharmaceutical Stock Slides 3.3% in Hong Kong

Dow Jones
·
Oct 08

Movement Alert|SBP GROUP Falls 3.08% in Regular Trading, Following Sector Adjustment

Market Focus
·
Oct 08

Hong Kong Stocks Climb, Led by Pharmaceutical, Tech Stocks

Reuters
·
Oct 06

Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts

Stock News
·
Oct 06

HK Movers | Innovative Drug Stocks Rally Broadly; GENSCRIPT BIO Jumps Over 6% to New High

Tiger Newspress
·
Oct 06

Movement Alert|SBP GROUP Rises 3.15% in Regular Trading, Citigroup Retains Buy Rating on STADA Collaboration

Market Focus
·
Oct 06

Sino Biopharmaceutical Stock Falls 2.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 02

Movement Alert|SBP GROUP Falls 4.29% in Regular Trading, Trading at HK$5.48

Market Focus
·
Oct 02

Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong

Dow Jones
·
Sep 30

SBP Group Shares Surge Over 4% Intraday; Citi Maintains "Buy" Rating

Deep News
·
Sep 30

Sino Biopharmaceutical Jumps Over 4% as Citi Highlights STADA Partnership to Share Licensing Drug Profits Through Production Supply

Stock News
·
Sep 30

Movement Alert|SBP GROUP Rises 3.33% in Regular Trading, STADA Biosimilar Partnership Continues to Drive Momentum

Market Focus
·
Sep 30

Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, "Buy" Rating Maintained

Stock News
·
Sep 29

Sino Biopharm Unit CTTQ Presents Phase 3 APEX-Breast01 Data for Tqb2102 in HER2-Low Breast Cancer at ESMO 2026

Reuters
·
Sep 29

Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment

Stock News
·
Sep 29

Movement Alert|SBP GROUP Rises 3.18% in Regular Trading, Subsidiary Partners with STADA on Biosimilar Strategic Collaboration

Market Focus
·
Sep 29